Heidi Giordano

5.6k total citations
42 papers, 1.1k citations indexed

About

Heidi Giordano is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Heidi Giordano has authored 42 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Reproductive Medicine. Recurrent topics in Heidi Giordano's work include PARP inhibition in cancer therapy (34 papers), Ovarian cancer diagnosis and treatment (11 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Heidi Giordano is often cited by papers focused on PARP inhibition in cancer therapy (34 papers), Ovarian cancer diagnosis and treatment (11 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Heidi Giordano collaborates with scholars based in United States, United Kingdom and Canada. Heidi Giordano's co-authors include Sandra Goble, Lindsey Rolfe, M. Sivaraja, M G Peterson, Susan M. Domchek, Robert DeLotto, Li Liang, Rebecca Kristeleit, Lara Maloney and Kevin Lin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Development.

In The Last Decade

Heidi Giordano

42 papers receiving 1.1k citations

Peers

Countries citing papers authored by Heidi Giordano

Since Specialization

Citations

This map shows the geographic impact of Heidi Giordano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Giordano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Giordano more than expected).

Fields of papers citing papers by Heidi Giordano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Giordano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Giordano. The network helps show where Heidi Giordano may publish in the future.

Co-authorship network of co-authors of Heidi Giordano

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Giordano. A scholar is included among the top collaborators of Heidi Giordano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Giordano. Heidi Giordano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib 2022 ·Clinical Pharmacokinetics ·Mingxiang Liao, (unknown), Heidi Giordano, Thomas C. Harding, Lara Maloney, Andrew D. Simmons, Jim Xiao	8
2	Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors 2022 ·Cancer Chemotherapy and Pharmacology ·Michelle Green, (unknown), Sandra Goble, Heidi Giordano, Lara Maloney, Andrew D. Simmons, (unknown), Thomas C. Harding, Jim Xiao	5
3	547P Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131) 2020 ·Annals of Oncology ·Timothy A. Yap, Erika Hamilton, Todd M. Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, (unknown), (unknown), (unknown), Kenton Wride, Heidi Giordano, Geoffrey I. Shapiro	5
4	Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation 2018 ·JCO Precision Oncology ·Rachna T. Shroff, Andrew Hendifar, Robert R. McWilliams, Ravit Geva, Ron Epelbaum, Lindsey Rolfe, Sandra Goble, Kevin Lin, Andrew V. Biankin, Heidi Giordano, Robert H. Vonderheide, Susan M. Domchek	137
5	A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors 2017 ·Clinical Cancer Research ·Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmañà, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Fernández Montés, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, (unknown), Lindsey Rolfe, Ronnie Shapira‐Frommer	186
6	ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer 2017 ·Annals of Oncology ·Rebecca Kristeleit, Domenica Lorusso, Ana Oaknin, Tamar Safra, Elizabeth M. Swisher, Igor Bondarenko, Tomasz Huzarski, Jaroslav Klát, Vladimir Moiseyenko, Ròbert Póka, (unknown), (unknown), Lara Maloney, Sandra Goble, (unknown), (unknown), Heidi Giordano, Amit M. Oza	1
7	ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC) 2017 ·Annals of Oncology ·Jonathan A. Ledermann, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, (unknown), Giovanni Scambia, Alexandra Léary, Robert W. Holloway, David M. O’Malley, T. Cameron, Lara Maloney, Sandra Goble, Kevin Lin, Jing Sun, Heidi Giordano, Robert L. Coleman	5
8	A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours 2017 ·British Journal of Cancer ·Richard H. Wilson, (unknown), Mark R. Middleton, L. Rhoda Molife, James Spicer, Véronique Dièras, Patricia Roxburgh, Heidi Giordano, Sarah Jaw‐Tsai, Sandra Goble, Ruth Plummer	60
9	Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) 2016 ·Annals of Oncology ·(unknown), Ronnie Shapira‐Frommer, Ana Oaknin, Judith Balmañà, Isabelle Laure Ray-Coquard, Susan M. Domchek, Anna V. Tinker, Cesar M. Castro, Stephen Welch, Andrés Poveda, K.M. Bell-McGuinn, Gottfried E. Konecny, Heidi Giordano, Lara Maloney, Sandra Goble, Lindsey Rolfe, (unknown)	21
10	Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial. 2016 ·Journal of Clinical Oncology ·Anna Piskorz, Kevin Lin, (unknown), Elaina Mann, Amit M. Oza, Robert L. Coleman, David M. O’Malley, Michael Friedländer, Janiel M. Cragun, Ling Ma, Heidi Giordano, Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, James D. Brenton	13
11	Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation 2015 ·Cancer Research ·Susan M. Domchek, Robert R. McWilliams, Andrew Hendifar, Rachna T. Shroff, Lawrence Leichman, Ron Epelbaum, Ravit Geva, George Kim, Steven R. Alberts, Robert A. Wolff, Andrew R. Allen, Heidi Giordano, Mitch Raponi, Jeff Isaacson, Lindsey Rolfe, Andrew V. Biankin, Robert H. Vonderheide	3
12	Phase 1/2 study of oral rucaparib: Final phase 1 results. 2014 ·Journal of Clinical Oncology ·Rebecca Kristeleit, Howard A. Burris, Patricia LoRusso, Manish R. Patel, Uzma Asghar, (unknown), (unknown), Jeffrey R. Infante, John Hilton, Sara M. Tolaney, Muaiad Kittaneh, Heidi Giordano, (unknown), Sarah Jaw‐Tsai, Geoffrey I. Shapiro	21
13	215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib 2014 ·European Journal of Cancer ·E. Swisher, James D. Brenton, (unknown), Amit M. Oza, Robert L. Coleman, David M. O’Malley, Gottfried E. Konecny, Lin Ma, Maria I. Harrell, (unknown), Andrea Wahner Hendrickson, (unknown), Mitch Raponi, E Mann, Heidi Giordano, Lara Maloney, Lindsey Rolfe, Iain A. McNeish	9
14	A phase 1 study of oral rucaparib in combination with carboplatin 2013 ·European Journal of Cancer ·Patricia Roxburgh, L Rhoda Molife, Anubha Gupta, (unknown), T. R. J. Evans, Nicola Cresti, Heidi Giordano, (unknown), Sarah Jaw‐Tsai, Ruth Plummer	2
15	Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors. 2013 ·Molecular Cancer Therapeutics ·Geoffrey I. Shapiro, (unknown), Mark R. Middleton, Howard A. Burris, L Rhoda Molife, (unknown), Ryann Wilson, P. LoRusso, James Spicer, V. Diéras, Maulik Patel, (unknown), (unknown), Heidi Giordano, Ann Allen, Sarah Jaw‐Tsai, Ruth Plummer	3
16	Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study 2010 ·Blood ·Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle, Elias Jabbour, (unknown), Kyle J. MacBeth, Eric Laille, Heidi Giordano, Hagop M. Kantarjian, Barry Skikne	7
17	Interallelic Complementation at theDrosophila melanogaster gastrulation defectiveLocus Defines Discrete Functional Domains of the Protein 2001 ·Genetics ·(unknown), Heidi Giordano, Yvonne DeLotto, Robert DeLotto	15
18	Inhibition of Herpes Simplex Virus Replication by a 2-Amino Thiazole via Interactions with the Helicase Component of the UL5-UL8-UL52 Complex 1998 ·Journal of Virology ·(unknown), Li Liang, Heidi Giordano, M. Sivaraja, M G Peterson	107
19	Spatial regulation of Drosophila Snake protease activity in the generation of dorsal-ventral polarity 1995 ·Development ·Cynthia L. Smith, Heidi Giordano, (unknown), Robert DeLotto	23
20	Mutational analysis of the Drosophila snake protease: an essential role for domains within the proenzyme polypeptide chain. 1994 ·Genetics ·Cynthia L. Smith, Heidi Giordano, Robert DeLotto	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact